Search
Phenoxymethylpenicillin
go.drugbank.com/drugs/DB00417ApprovedInvestigationalVet approvedAn orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G-sensitive microorganisms … While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use
Gepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. … [A192834,A192888,A192837,A192891,A192894] Bevacizumab is a humanized monoclonal IgG antibody that inhibits angiogenesis by binding and neutralizing VEGF-A.
Calcium chloride
go.drugbank.com/drugs/DB01164ApprovedInvestigationalIt can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers.
Palovarotene
go.drugbank.com/drugs/DB05467ApprovedIt first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L40010] On August 16, 2023, palovarotene was also approved by the FDA for the management of HO associated with FOP.[L47845]
Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalModifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072
Zilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigational[L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Raxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigational[A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272] … It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnOn September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.
Etafedrine
go.drugbank.com/drugs/DB11587ApprovedEthylephedrine is be formed by alkylating ephedrine with ethyl iodide. The hydrochloride is be prepared by passing hydrogen chloride through a solution of ethylephedrine in diethyl ether [F6]. … It acts by narrowing blood vessels in the nasal passages, helping to relieve nasal congestion [F6].